Table 4.
Cost-effectiveness of RZV vs no vaccination for various age cohorts
| Age cohort | ≥ 50 YOA | ≥ 60 YOA | ≥ 70 YOA |
|---|---|---|---|
| HZ cases avoided | 57,071 | 50,737 | 41,511 |
| PHN cases avoided | 10,294 | 9,836 | 8,379 |
| Complications other than PHN avoided | 6,991 | 6,215 | 5,085 |
| HZ-related deaths avoided | 15 | 19 | 22 |
| Discounted life-years gained | 67 | 87 | 102 |
| Discounted QALYs gained | 1,858 | 1,881 | 1,683 |
| Total costs (discounted) | 58,959,402 | 61,986,534 | 66,766,789 |
| ICER | €31,735/QALY | €32,956/QALY | €39,676/QALY |
| Direct and indirect costs | |||
| updated to 2020 values | |||
| Total costs (discounted) | €57,054,928 | €60,449,516 | €65,810,032 |
| ICER | €30,710/QALY | €32,139/QALY | €39,107/QALY |
| Vaccine Price | |||
| €133.62/dose | |||
| Total costs (discounted) | €73,084,026 | €76,478,615 | €81,839,131 |
| ICER | €39,337/ QALY |
€40,661/ QALY |
€48,632/ QALY |
HZ: herpes zoster; PHN: postherpetic neuralgia; RZV: recombinant zoster vaccine; YOA: years of age; QALY: quality-adjusted life year; ICER: incremental cost-effectiveness ratio.
The 2021 price of RZV is €133.62 per dose (i.e. average price to be paid by payers for one dose across all 17 health care regions via office supply) corresponding to a price to wholesaler (PTW) of €106.18 per dose.